Voluntary announcement - collaboration and license agreement with amberstone for two T Cell Engager products
Filed with HKEX · Stock code 2696 · · 3 pages · English
Shanghai Henlius Biotech, Inc. 上海復宏漢霖生物技術股份有限公司 (A joint stock company incorporated in the People’s Republic of China with limited liability) (Stock code: 2696) VOLUNTARY ANNOUNCEMENT COLLABORATION AND LICENSE AGREEMENT WITH AMBERSTONE FOR TWO T CELL ENGAGER PRODUCTS A. INTRODUCTION The board of directors (the “Board”) of Shanghai Henlius Biotech, Inc. (the “Company”) is pleased to announce that o
Shanghai Henlius Biotech, Inc. on 6ix
Earlier from Shanghai Henlius Biotech
- Henlius Reports 2026 Interim Results: Sustained Profitability Leap, Advancing Global Value Validation
- Henlius Reports 2026 Interim Results: Sustained Profitability Leap, Advancing Global Value Validation, and Accelerating Progress Towards C-MNC
- Henlius and Sandoz Enter Strategic Collaboration to Unlock Global Value of Biosimilars Platform
- FDA Approves Shanghai Henlius Biotech IND For Cetuximab Biosimilar
- Henlius Announces IND Approval from NMPA for Its Proprietary c-Met/EGFR Bispecific ADC HLX48
Later from Shanghai Henlius Biotech
- Interim report 2026
- (1) Changes in non-executive director and independent non-executive director (2) appointment of chairman of the board and changes in composition of the board committees
- List of directors and their roles and functions
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
Follow Shanghai Henlius Biotech into a list and get an email when it puts out news.
Follow Shanghai Henlius Biotech